Personalizing Aspirin Therapy in Peripheral Arterial Disease Patients
Status:
Not yet recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Antiplatelet therapies are important to decrease the morbidity and mortality associated with
Peripheral Arterial Disease (PAD) through the prevention of thrombus formation. Aspirin (ASA)
is a readily available and affordable antiplatelet medication that can help reduce adverse
cardiovascular events by up to 25%. However, 25-60% of PAD patients are "ASA insensitive"
having a lower than normal ability to inhibit platelet aggregation after standard aspirin
dosing. In a previous study conducted by our lab, we were able to demonstrate a methodology
for personalizing antiplatelet therapy using two platelet function tests, Platelet Function
Analyzer-100 (PFA 100) and Light Transmission Aggregometry (LTA). To investigate this
methodology further, we would like to conduct a pilot study on two cohorts of patients, one
population continuing with their current medications (81mg ASA), and a second group who will
get personalized antiplatelet therapy using our methodology (81-325mg ASA). In this study,
150 PAD patients taking 81mg Aspirin therapy presenting for clinical follow-up, or in-patient
intervention, in vascular clinics or the emergency room, will be recruited to our study. 75
patients will be randomly assigned undergo platelet analysis using PFA-200 and LTA, and will
have their antiplatelet therapy personalized. Patients will then be followed up in order to
see if the patients with personalized therapy have better platelet inhibition. This study
will allow us to help personalize antiplatelet therapy in PAD patients, allowing for better
patient outcomes and decreased adverse cardiovascular events.
Phase:
N/A
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto